Isocitrate Dehydrogenase Mutation and ( R )-2-Hydroxyglutarate: From Basic Discovery to Therapeutics Development

Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation

Vander Heiden, M. G., Cantley, L. C., & Thompson, C. B. (2009) · Science · doi:10.1126/science.1160809 · Cited by 16,197 · see citing works

On the origin of cancer cells

Warburg, O. (1956) · Science · doi:10.1126/science.123.3191.309 · Cited by 13,425 · see citing works

Targeting HIF-1 for cancer therapy

Semenza, G. L. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1187 · Cited by 6,717 · see citing works

An Integrated Genomic Analysis of Human Glioblastoma Multiforme

Parsons, D. W., Jones, S., Zhang, X., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.-M., Gallia, G. L., et al. (2008) · Science · doi:10.1126/science.1164382 · Cited by 5,857 · see citing works

<i>IDH1</i> and <i>IDH2</i> Mutations in Gliomas

Yan, H., Parsons, D. W., Jin, G., McLendon, R., Rasheed, B. A., Yuan, W., Kos, I., Batinic-Haberle, I., Jones, S., Riggins, G. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808710 · Cited by 5,847 · see citing works

Conversion of 5-Methylcytosine to 5-Hydroxymethylcytosine in Mammalian DNA by MLL Partner TET1

Tahiliani, M., Koh, K. P., Shen, Y., Pastor, W. A., Bandukwala, H., Brudno, Y., Agarwal, S., Iyer, L. M., Liu, D. R., Aravind, L., et al. (2009) · Science · doi:10.1126/science.1170116 · Cited by 5,836 · see citing works

Genomic classification and prognosis in acute myeloid leukemia

Papaemmanuil, E., Gerstung, M., Bullinger, L., Gaidzik, V. I., Paschka, P., Roberts, N. D., Potter, N. E., Heuser, M., Thol, F., Bolli, N., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1516192 · Cited by 4,350 · see citing works

Cancer-associated IDH1 mutations produce 2-hydroxyglutarate

Dang, L., White, D. W., Gross, S., Bennett, B. D., Bittinger, M. A., Driggers, E. M., Fantin, V. R., Jang, H. G., Jin, S., Keenan, M. C., et al. (2009) · Nature · doi:10.1038/nature08617 · Cited by 4,154 · see citing works

Metabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not Anticipate

Ward, P. S., & Thompson, C. B. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.02.014 · Cited by 3,233 · see citing works

Oncometabolite 2-Hydroxyglutarate Is a Competitive Inhibitor of α-Ketoglutarate-Dependent Dioxygenases

Xu, W., Yang, H., Liu, Y., Yang, Y., Wang, P., Kim, S.-H., Ito, S., Yang, C., Wang, P., Xiao, M.-T., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2010.12.014 · Cited by 2,875 · see citing works

Leukemic IDH1 and IDH2 Mutations Result in a Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic Differentiation

Figueroa, M. E., Abdel-Wahab, O., Lu, C., Ward, P. S., Patel, J., Shih, A., Li, Y., Bhagwat, N., Vasanthakumar, A., Fernandez, H. F., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.11.015 · Cited by 2,766 · see citing works

Role of Tet proteins in 5mC to 5hmC conversion, ES-cell self-renewal and inner cell mass specification

Ito, S., D’Alessio, A. C., Taranova, O., Hong, K., Sowers, L. C., & Zhang, Y. (2010) · Nature · doi:10.1038/nature09303 · Cited by 2,542 · see citing works

Identification of a CpG Island Methylator Phenotype that Defines a Distinct Subgroup of Glioma

Noushmehr, H., Weisenberger, D. J., Diefes, K., Phillips, H. S., Pujara, K., Berman, B. P., Pan, F., Pelloski, C. E., Sulman, E. P., Bhat, K. P., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.03.017 · Cited by 2,337 · see citing works

The Common Feature of Leukemia-Associated IDH1 and IDH2 Mutations Is a Neomorphic Enzyme Activity Converting α-Ketoglutarate to 2-Hydroxyglutarate

Ward, P. S., Patel, J., Wise, D. R., Abdel-Wahab, O., Bennett, B. D., Coller, H. A., Cross, J. R., Fantin, V. R., Hedvat, C. V., Perl, A. E., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.01.020 · Cited by 2,020 · see citing works

IDH mutation impairs histone demethylation and results in a block to cell differentiation

Lu, C., Ward, P. S., Kapoor, G. S., Rohle, D., Turcan, S., Abdel-Wahab, O., Edwards, C. R., Khanin, R., Figueroa, M. E., Melnick, A., et al. (2012) · Nature · doi:10.1038/nature10860 · Cited by 1,985 · see citing works

IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype

Turcan, S., Rohle, D., Goenka, A., Walsh, L. A., Fang, F., Yilmaz, E., Campos, C., Fabius, A. W. M., Lu, C., Ward, P. S., et al. (2012) · Nature · doi:10.1038/nature10866 · Cited by 1,974 · see citing works

Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia

Metallo, C. M., Gameiro, P. A., Bell, E. L., Mattaini, K. R., Yang, J., Hiller, K., Jewell, C. M., Johnson, Z. R., Irvine, D. J., Guarente, L., et al. (2012) · Nature · doi:10.1038/nature10602 · Cited by 1,791 · see citing works

Mutation in <i>TET2</i> in Myeloid Cancers

Delhommeau, F., Dupont, S., Valle, V. D., James, C., Trannoy, S., Massé, A., Kosmider, O., Le Couedic, J.-P., Robert, F., Alberdi, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810069 · Cited by 1,776 · see citing works

Reductive carboxylation supports growth in tumour cells with defective mitochondria

Mullen, A. R., Wheaton, W. W., Jin, E. S., Chen, P.-H., Sullivan, L. B., Cheng, T., Yang, Y., Linehan, W. M., Chandel, N. S., & DeBerardinis, R. J. (2012) · Nature · doi:10.1038/nature10642 · Cited by 1,328 · see citing works

DNA methylation and gene silencing in cancer

Baylin, S. B. (2005) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0354 · Cited by 1,156 · see citing works

An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells

Rohle, D., Popovici-Muller, J., Palaskas, N., Turcan, S., Grommes, C., Campos, C., Tsoi, J., Clark, O., Oldrini, B., Komisopoulou, E., et al. (2013) · Science · doi:10.1126/science.1236062 · Cited by 1,153 · see citing works

Glioma-Derived Mutations in <i>IDH1</i> Dominantly Inhibit IDH1 Catalytic Activity and Induce HIF-1α

Zhao, S., Lin, Y., Xu, W., Jiang, W., Zha, Z., Wang, P., Yu, W., Li, Z., Gong, L., Peng, Y., et al. (2009) · Science · doi:10.1126/science.1170944 · Cited by 1,119 · see citing works

Quantitative flux analysis reveals folate-dependent NADPH production

Fan, J., Ye, J., Kamphorst, J. J., Shlomi, T., Thompson, C. B., & Rabinowitz, J. D. (2014) · Nature · doi:10.1038/nature13236 · Cited by 1,114 · see citing works

Analysis of the IDH1 codon 132 mutation in brain tumors

Balss, J., Meyer, J., Mueller, W., Korshunov, A., Hartmann, C., & von Deimling, A. (2008) · Acta Neuropathologica · doi:10.1007/s00401-008-0455-2 · Cited by 1,036 · see citing works

The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases

Chowdhury, R., Yeoh, K. K., Tian, Y., Hillringhaus, L., Bagg, E. A., Rose, N. R., Leung, I. K. H., Li, X. S., Woon, E. C. Y., Yang, M., et al. (2011) · The EMBO Reports · doi:10.1038/embor.2011.43 · Cited by 1,035 · see citing works

<i>IDH1</i> and <i>IDH2</i> mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours

Amary, M. F., Bacsi, K., Maggiani, F., Damato, S., Halai, D., Berisha, F., Pollock, R., O'Donnell, P., Grigoriadis, A., Diss, T., et al. (2011) · The Journal of Pathology · doi:10.1002/path.2913 · Cited by 1,023 · see citing works

Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation

Wang, F., Travins, J., DeLaBarre, B., Penard-Lacronique, V., Schalm, S., Hansen, E., Straley, K., Kernytsky, A., Liu, W., Gliser, C., et al. (2013) · Science · doi:10.1126/science.1234769 · Cited by 804 · see citing works

Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations

Gross, S., Cairns, R. A., Minden, M. D., Driggers, E. M., Bittinger, M. A., Jang, H. G., Sasaki, M., Jin, S., Schenkein, D. P., Su, S. M., et al. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20092506 · Cited by 736 · see citing works

Frequent Mutation of Isocitrate Dehydrogenase<i>(IDH)1</i>and<i>IDH2</i>in Cholangiocarcinoma Identified Through Broad-Based Tumor Genotyping

Borger, D. R., Tanabe, K. K., Fan, K. C., Lopez, H. U., Fantin, V. R., Straley, K. S., Schenkein, D. P., Hezel, A. F., Ancukiewicz, M., Liebman, H. M., et al. (2012) · The Oncologist · doi:10.1634/theoncologist.2011-0386 · Cited by 728 · see citing works

Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation

Koivunen, P., Lee, S., Duncan, C. G., Lopez, G., Lu, G., Ramkissoon, S., Losman, J. A., Joensuu, P., Bergmann, U., Gross, S., et al. (2012) · Nature · doi:10.1038/nature10898 · Cited by 727 · see citing works

( <i>R</i> )-2-Hydroxyglutarate Is Sufficient to Promote Leukemogenesis and Its Effects Are Reversible

Losman, J.-A., Looper, R. E., Koivunen, P., Lee, S., Schneider, R. K., McMahon, C., Cowley, G. S., Root, D. E., Ebert, B. L., & Kaelin, W. G. (2013) · Science · doi:10.1126/science.1231677 · Cited by 703 · see citing works

Reductive carboxylation supports redox homeostasis during anchorage-independent growth

Jiang, L., Shestov, A. A., Swain, P., Yang, C., Parker, S. J., Wang, Q. A., Terada, L. S., Adams, N. D., McCabe, M. T., Pietrak, B., et al. (2016) · Nature · doi:10.1038/nature17393 · Cited by 582 · see citing works

Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia

Chan, S. M., Thomas, D., Corces, M. R., Xavy, S., Rastogi, S., Hong, W., Zhao, F., Medeiros, B. C., Tyvoll, D. A., & Majeti, R. (2015) · Nature Medicine · doi:10.1038/nm.3788 · Cited by 580 · see citing works

Tracing compartmentalized NADPH metabolism in the cytosol and mitochondria of mammalian cells

Lewis, C. A., Parker, S. J., Fiske, B. P., McCloskey, D., Gui, D. Y., Green, C. R., Vokes, N. I., Feist, A. M., Vander Heiden, M. G., & Metallo, C. M. (2014) · Molecular Cell · doi:10.1016/j.molcel.2014.05.008 · Cited by 562 · see citing works

Hypoxia Induces Production of L-2-Hydroxyglutarate

Intlekofer, A. M., Dematteo, R. G., Venneti, S., Finley, L. W. S., Lu, C., Judkins, A. R., Rustenburg, A. S., Grinaway, P. B., Chodera, J. D., Cross, J. R., et al. (2015) · Cell Metabolism · doi:10.1016/j.cmet.2015.06.023 · Cited by 513 · see citing works

Inhibition of Glutaminase Preferentially Slows Growth of Glioma Cells with Mutant IDH1

Seltzer, M. J., Bennett, B. D., Joshi, A. D., Gao, P., Thomas, A. G., Ferraris, D. V., Tsukamoto, T., Rojas, C. J., Slusher, B. S., Rabinowitz, J. D., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1666 · Cited by 513 · see citing works

Breaking Cryo-EM Resolution Barriers to Facilitate Drug Discovery

Merk, A., Bartesaghi, A., Banerjee, S., Falconieri, V., Rao, P., Davis, M. I., Pragani, R., Boxer, M. B., Earl, L. A., Milne, J. L. S., et al. (2016) · Cell · doi:10.1016/j.cell.2016.05.040 · Cited by 498 · see citing works

Mutant IDH inhibits HNF-4α to block hepatocyte differentiation and promote biliary cancer

Saha, S. K., Parachoniak, C. A., Ghanta, K. S., Fitamant, J., Ross, K. N., Najem, M. S., Gurumurthy, S., Akbay, E. A., Sia, D., Cornellà, H., et al. (2014) · Nature · doi:10.1038/nature13441 · Cited by 460 · see citing works

Profiling the effects of isocitrate dehydrogenase 1 and 2 mutations on the cellular metabolome

Reitman, Z. J., Jin, G., Karoly, E. D., Spasojevic, I., Yang, J., Kinzler, K. W., He, Y., Bigner, D. D., Vogelstein, B., & Yan, H. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1019393108 · Cited by 449 · see citing works

Structural studies on 2-oxoglutarate oxygenases and related double-stranded β-helix fold proteins

Clifton, I. J., McDonough, M. A., Ehrismann, D., Kershaw, N. J., Granatino, N., & Schofield, C. J. (2006) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2006.01.024 · Cited by 444 · see citing works

Evidence for Sequenced Molecular Evolution of IDH1 Mutant Glioblastoma From a Distinct Cell of Origin

Lai, A., Kharbanda, S., Pope, W. B., Tran, A. N., Solis, O. E., Peale, F. V., Jr., Forrest, W. F., Pujara, K., Carrillo, J., Pandita, A., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.8715 · Cited by 432 · see citing works

The ever-expanding role of HIF in tumour and stromal biology

LaGory, E. L., & Giaccia, A. J. (2016) · Nature Cell Biology · doi:10.1038/ncb3330 · Cited by 432 · see citing works

Cytosolic NADP+-dependent isocitrate dehydrogenase status modulates oxidative damage to cells

Lee, S. M., Koh, H., Park, D., Song, B. J., Huh, T., & Park, J. (2002) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(02)00815-8 · Cited by 422 · see citing works

Structures of Human Cytosolic NADP-dependent Isocitrate Dehydrogenase Reveal a Novel Self-regulatory Mechanism of Activity

Xu, X., Zhao, J., Xu, Z., Peng, B., Huang, Q., Arnold, E., & Ding, J. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m404298200 · Cited by 407 · see citing works

IDH mutations in glioma and acute myeloid leukemia

Dang, L., Jin, S., & Su, S.-S. M. (2010) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2010.07.002 · Cited by 368 · see citing works

Isocitrate dehydrogenase mutations in myeloid malignancies

Medeiros, B. C., Fathi, A. T., Dinardo, C. D., Pollyea, D. A., Chan, S. M., & Swords, R. T. (2016) · Leukemia · doi:10.1038/leu.2016.275 · Cited by 348 · see citing works

D-2-hydroxyglutarate produced by mutant IDH1 perturbs collagen maturation and basement membrane function

Sasaki, M., Knobbe, C. B., Itsumi, M., Elia, A. J., Harris, I. S., Chio, I. I. C., Cairns, R. A., McCracken, S., Wakeham, A., Haight, J., et al. (2012) · Genes &amp; Development · doi:10.1101/gad.198200.112 · Cited by 296 · see citing works

Progress in understanding 2‐hydroxyglutaric acidurias

Kranendijk, M., Struys, E. A., Salomons, G. S., Van der Knaap, M. S., & Jakobs, C. (2012) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-012-9462-5 · Cited by 292 · see citing works

Isocitrate dehydrogenase mutations in gliomas

Waitkus, M. S., Diplas, B. H., & Yan, H. (2015) · Neuro-Oncology · doi:10.1093/neuonc/nov136 · Cited by 282 · see citing works

Cytosolic NADP+-dependent Isocitrate Dehydrogenase Plays a Key Role in Lipid Metabolism

Koh, H., Lee, S., Son, B.-G., Lee, S.-H., Ryoo, Z. Y., Chang, K., Park, J., Park, D., Song, B. J., Veech, R. L., et al. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m402260200 · Cited by 253 · see citing works

NADP+-IDH Mutations Promote Hypersuccinylation that Impairs Mitochondria Respiration and Induces Apoptosis Resistance

Li, F., He, X., Ye, D., Lin, Y., Yu, H., Yao, C., Huang, L., Zhang, J., Wang, F., Xu, S., et al. (2015) · Molecular Cell · doi:10.1016/j.molcel.2015.10.017 · Cited by 244 · see citing works

Efficient induction of differentiation and growth inhibition in IDH1 mutant glioma cells by the DNMT inhibitor decitabine

Turcan, S., Fabius, A. W. M., Borodovsky, A., Pedraza, A., Brennan, C., Huse, J., Viale, A., Riggins, G. J., & Chan, T. A. (2013) · Oncotarget · doi:10.18632/oncotarget.1412 · Cited by 240 · see citing works

BIOSYNTHESIS OF TRICARBOXYLIC ACIDS BY CARBON DIOXIDE FIXATION

Ochoa, S. (1948) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)57383-x · Cited by 227 · see citing works

Mutant IDH1 promotes leukemogenesis in vivo and can be specifically targeted in human AML

Chaturvedi, A., Araujo Cruz, M. M., Jyotsana, N., Sharma, A., Yun, H., Görlich, K., Wichmann, M., Schwarzer, A., Preller, M., Thol, F., et al. (2013) · Blood · doi:10.1182/blood-2013-03-491571 · Cited by 210 · see citing works

Lactate dehydrogenase A silencing in IDH mutant gliomas

Chesnelong, C., Chaumeil, M. M., Blough, M. D., Al-Najjar, M., Stechishin, O. D., Chan, J. A., Pieper, R. O., Ronen, S. M., Weiss, S., Luchman, H. A., et al. (2014) · Neuro-Oncology · doi:10.1093/neuonc/not243 · Cited by 210 · see citing works

Proton‐translocating transhydrogenase and NAD‐ and NADP‐linked isocitrate dehydrogenases operate in a substrate cycle which contributes to fine regulation of the tricarboxylic acid cycle activity in mitochondria

Sazanov, L. A., & Jackson, J. B. (1994) · FEBS Letters · doi:10.1016/0014-5793(94)00370-x · Cited by 205 · see citing works

Discovery of the First Potent Inhibitors of Mutant IDH1 That Lower Tumor 2-HG in Vivo

Popovici-Müller, J. V., Saunders, J. O., Salituro, F. G., Travins, J. M., Yan, S., Zhao, F., Größ, S., Dang, L., Yen, K. E., Yang, H., et al. (2012) · ACS Medicinal Chemistry Letters · doi:10.1021/ml300225h · Cited by 204 · see citing works

Human Phosphoglycerate Dehydrogenase Produces the Oncometabolite d -2-Hydroxyglutarate

Fan, J., Teng, X., Liu, L., Mattaini, K. R., Looper, R., Heiden, M. G. V., & Rabinowitz, J. D. (2014) · ACS Chemical Biology · doi:10.1021/cb500683c · Cited by 201 · see citing works

<i>IDH2</i> Mutations in Patients with <scp>d</scp> -2-Hydroxyglutaric Aciduria

Kranendijk, M., Struys, E. A., van Schaftingen, E., Gibson, K. M., Kanhai, W. A., van der Knaap, M. S., Amiel, J., Buist, N. R., Das, A. M., de Klerk, J. B., et al. (2010) · Science · doi:10.1126/science.1192632 · Cited by 195 · see citing works

Identification of additional IDH mutations associated with oncometabolite R(−)-2-hydroxyglutarate production

Ward, P. S., Cross, J. R., Lü, C., Weigert, O., Abdel-Wahab, O. I., Levine, R. L., Weinstock, D. M., Sharp, K. A., & Thompson, C. B. (2011) · Oncogene · doi:10.1038/onc.2011.416 · Cited by 191 · see citing works

New IDH1 mutant inhibitors for treatment of acute myeloid leukemia

Okoye-Okafor, U. C., Bartholdy, B., Cartier, J., Gao, E. N., Pietrak, B., Rendina, A. R., Rominger, C., Quinn, C., Smallwood, A., Wiggall, K. J., et al. (2015) · Nature Chemical Biology · doi:10.1038/nchembio.1930 · Cited by 180 · see citing works

isoCitric dehydrogenase and glutamic acid synthesis in animal tissues

Adler, E., Euler, H. V., Günther, G., & Plass, M. (1939) · Biochemical Journal · doi:10.1042/bj0331028 · Cited by 161 · see citing works

Hydroxyglutaric aciduria and malignant brain tumor: a case report and literature review

Aghili, M., Zahedi, F., & Rafiee, E. (2009) · Journal of Neuro-Oncology · doi:10.1007/s11060-008-9706-2 · Cited by 159 · see citing works

Inhibition of glutaminase selectively suppresses the growth of primary acute myeloid leukemia cells with IDH mutations

Emadi, A., Jun, S. A., Tsukamoto, T., Fathi, A. T., Minden, M. D., & Dang, C. V. (2013) · Experimental Hematology · doi:10.1016/j.exphem.2013.12.001 · Cited by 152 · see citing works

l ‐2‐Hydroxyglutaric aciduria, a defect of metabolite repair

Rzem, R., Vincent, M., SCHAFTINGEN, E. V., & Veiga‐da‐Cunha, M. (2007) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-007-0487-0 · Cited by 149 · see citing works

Radioprotection of <i>IDH1</i> -Mutated Cancer Cells by the IDH1-Mutant Inhibitor AGI-5198

Molenaar, R. J., Botman, D., Smits, M. A., Hira, V. V., van Lith, S. A., Stap, J., Henneman, P., Khurshed, M., Lenting, K., Mul, A. N., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-3603 · Cited by 148 · see citing works

Measurement of Urinary d- and l-2-Hydroxyglutarate Enantiomers by Stable-Isotope-Dilution Liquid Chromatography–Tandem Mass Spectrometry after Derivatization with Diacetyl-l-Tartaric Anhydride

Struys, E. A., Jansen, E. E. W., Verhoeven‐Duif, N. M., & Jakobs, C. (2004) · Clinical Chemistry · doi:10.1373/clinchem.2004.033399 · Cited by 147 · see citing works

Selective Inhibition of Mutant Isocitrate Dehydrogenase 1 (IDH1) via Disruption of a Metal Binding Network by an Allosteric Small Molecule

Deng, G., Shen, J., Yin, M., McManus, J., Mathieu, M., Gee, P., He, T., Shi, C., Bedel, O., McLean, L. R., et al. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.608497 · Cited by 138 · see citing works

D‐2‐hydroxyglutaric aciduria: Case report and biochemical studies

Chalmers, R. A., Lawson, A. M., Watts, R. W. E., Tavill, A. S., Kamerling, J. P., Hey, E., & Ogilvie, D. (1980) · Journal of Inherited Metabolic Disease · doi:10.1007/bf02312516 · Cited by 135 · see citing works

NMDA receptor activation and respiratory chain complex V inhibition contribute to neurodegeneration in d ‐2‐hydroxyglutaric aciduria

Kölker, S., Pawlak, V., Ahlemeyer, B., Okun, J. G., Hörster, F., Mayatepek, E., Krieglstein, J., Hoffmann, G. F., & Köhr, G. (2002) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.2002.02055.x · Cited by 133 · see citing works

A novel alpha-ketoglutarate reductase activity of the serA-encoded 3-phosphoglycerate dehydrogenase of Escherichia coli K-12 and its possible implications for human 2-hydroxyglutaric aciduria

Zhao, G., & Winkler, M. E. (1996) · Journal of Bacteriology · doi:10.1128/jb.178.1.232-239.1996 · Cited by 129 · see citing works

<i>IDH1</i> Mutation Induces Reprogramming of Pyruvate Metabolism

Izquierdo-Garcia, J. L., Viswanath, P., Eriksson, P., Cai, L., Radoul, M., Chaumeil, M. M., Blough, M., Luchman, H. A., Weiss, S., Cairncross, J. G., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-0840 · Cited by 123 · see citing works

Quantitative metabolome analysis profiles activation of glutaminolysis in glioma with IDH1 mutation

Ohka, F., Ito, M., Ranjit, M., Senga, T., Motomura, A., Motomura, K., Saito, K., Kato, K., Kato, Y., Wakabayashi, T., et al. (2014) · Tumor Biology · doi:10.1007/s13277-014-1784-5 · Cited by 121 · see citing works

Activities of citrate synthase, NAD+-linked and NADP+-linked isocitrate dehydrogenases, glutamate dehydrogenase, aspartate aminotransferase and alanine aminotransferase in nervous tissues from vertebrates and invertebrates

Sugden, P. H., & Newsholme, E. A. (1975) · Biochemical Journal · doi:10.1042/bj1500105 · Cited by 113 · see citing works

Hominoid-specific enzyme GLUD2 promotes growth of IDH1 R132H glioma

Chen, R., Nishimura, M. C., Kharbanda, S., Peale, F., Deng, Y., Daemen, A., Forrest, W. F., Kwong, M., Hedehus, M., Hatzivassiliou, G., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1409653111 · Cited by 112 · see citing works

2-Hydroxyglutarate Production, but Not Dominant Negative Function, Is Conferred by Glioma-Derived NADP+-Dependent Isocitrate Dehydrogenase Mutations

Jin, G., Reitman, Z. J., Spasojevic, I., Batinic-Haberle, I., Yang, J., Schmidt-Kittler, O., Bigner, D. D., & Yan, H. (2011) · PLoS ONE · doi:10.1371/journal.pone.0016812 · Cited by 112 · see citing works

A Tale of Two Subunits: How the Neomorphic R132H IDH1 Mutation Enhances Production of αHG

Pietrak, B., Zhao, H., Qi, H., Quinn, C. J., Gao, E. N., Boyer, J. G., Concha, N. O., Brown, K., Duraiswami, C., Wooster, R. F., et al. (2011) · Biochemistry · doi:10.1021/bi200499m · Cited by 109 · see citing works

The mechanisms of reductive carboxylation reactions. Carbon dioxide or bicarbonate as substrate of nicotinamide-adenine dinucleotide phosphate-linked isocitrate dehydrogenase and ‘malic’ enzyme

Dalziel, K., & Londesborough, J. (1968) · Biochemical Journal · doi:10.1042/bj1100223 · Cited by 101 · see citing works

THE PREPARATION OF ISOCITRIC DEHYDROGENASE FROM MAMMALIAN HEART

Siebert, G., Dubuc, J., Warner, R. C., & Plaut, G. W. E. (1957) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)70882-x · Cited by 93 · see citing works

Biochemical, Cellular, and Biophysical Characterization of a Potent Inhibitor of Mutant Isocitrate Dehydrogenase IDH1

Davis, M. I., Größ, S., Shen, M., Straley, K. S., Pragani, R., Lea, W., Popovici-Müller, J. V., DeLaBarre, B., Artin, E., Thorne, N., et al. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.511030 · Cited by 93 · see citing works

Evidence for Clinical Differentiation and Differentiation Syndrome in Patients With Acute Myeloid Leukemia and IDH1 Mutations Treated With the Targeted Mutant IDH1 Inhibitor, AG-120

Birendra, K. C., & Dinardo, C. D. (2016) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2016.04.006 · Cited by 92 · see citing works

Reversibility of the mitochondrial isocitrate dehydrogenase reaction in the perfused rat liver. Evidence from isotopomer analysis of citric acid cycle intermediates.

Rosiers, C. D., Fernandez, C. A., David, F., & Brunengraber, H. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)46965-7 · Cited by 88 · see citing works

The Kinetics of Pig Heart Triphosphopyridine Nucleotide-Isocitrate Dehydrogenase

Uhr, M. L., Thompson, V. W., & Cleland, W. W. (1974) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)42719-1 · Cited by 88 · see citing works

Hif-2α is not essential for cell-autonomous hematopoietic stem cell maintenance

Guitart, A. V., Subramani, C., Armesilla-Diaz, A., Smith, G., Sepúlveda, C., Gezer, D., Vukovic, M., Dunn, K. M., Pollard, P. J., Holyoake, T. L., et al. (2013) · Blood · doi:10.1182/blood-2013-02-484923 · Cited by 87 · see citing works

Metabolic Reprogramming in Mutant IDH1 Glioma Cells

Izquierdo-García, J. L., Viswanath, P., Eriksson, P., Chaumeil, M. M., Pieper, R. O., Phillips, J. J., & Ronen, S. M. (2015) · PLoS ONE · doi:10.1371/journal.pone.0118781 · Cited by 84 · see citing works

Non-enzymatic chemistry enables 2-hydroxyglutarate-mediated activation of 2-oxoglutarate oxygenases

Tarhonskaya, H., Rydzik, A. M., Leung, I. K. H., Loik, N. D., Chan, M. C., Kawamura, A., McCullagh, J. S. O., Claridge, T. D. W., Flashman, E., & Schofield, C. J. (2014) · Nature Communications · doi:10.1038/ncomms4423 · Cited by 80 · cited 1× · see citing works

Theoretical evaluation of conformational preferences of NAD+ and NADH: an approach to understanding the stereospecificity of NAD+/NADH-dependent dehydrogenases

Wu, Y. D., & Houk, K. N. (1991) · Journal of the American Chemical Society · doi:10.1021/ja00007a002 · Cited by 77 · see citing works

Crystallographic Investigation and Selective Inhibition of Mutant Isocitrate Dehydrogenase

Zheng, B., Yao, Y., Liu, Z., Deng, L., Anglin, J. L., Jiang, H., Prasad, B. V. V., & Song, Y. (2013) · ACS Medicinal Chemistry Letters · doi:10.1021/ml400036z · Cited by 76 · see citing works

Glioma Cells with the IDH1 Mutation Modulate Metabolic Fractional Flux through Pyruvate Carboxylase

Izquierdo-García, J. L., Cai, L. M., Chaumeil, M. M., Eriksson, P., Robinson, A. E., Pieper, R. O., Phillips, J. J., & Ronen, S. M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0108289 · Cited by 73 · see citing works

Safety and Efficacy of AG-221, a Potent Inhibitor of Mutant IDH2 That Promotes Differentiation of Myeloid Cells in Patients with Advanced Hematologic Malignancies: Results of a Phase 1/2 Trial

Stein, E. M., Dinardo, C. D., Altman, J. K., Collins, R. H., DeAngelo, D. J., Kantarjian, H. M., Sekeres, M. A., Fathi, A. T., Flinn, I. W., Frankel, A. E., et al. (2015) · Blood · doi:10.1182/blood.v126.23.323.323 · Cited by 72 · see citing works

The Kinetics of Pig Heart Triphosphopyridine Nucleotide-Isocitrate Dehydrogenase

Northrop, D. B., & Cleland, W. W. (1974) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)42720-8 · Cited by 71 · see citing works

Mutant IDH1 Dysregulates the Differentiation of Mesenchymal Stem Cells in Association with Gene-Specific Histone Modifications to Cartilage- and Bone-Related Genes

Jin, Y., Elalaf, H., Watanabe, M., Tamaki, S., Hineno, S., Matsunaga, K., Woltjen, K., Kobayashi, Y., Nagata, S., Ikeya, M., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0131998 · Cited by 70 · see citing works

An IDH1 mutation inhibits growth of glioma cells via GSH depletion and ROS generation

Shi, J., Zuo, H., Ni, L., Xia, L., Zhao, L., Gong, M., Nie, D., Gong, P., Cui, D., Shi, W., et al. (2013) · Neurological Sciences · doi:10.1007/s10072-013-1607-2 · Cited by 67 · see citing works

The equilibrium constant of the isocitrate dehydrogenase reaction

Londesborough, J., & Dalziel, K. (1968) · Biochemical Journal · doi:10.1042/bj1100217 · Cited by 64 · see citing works

Isocitrate dehydrogenase and related oxidative decarboxylases

Dalziel, K. (1980) · FEBS Letters · doi:10.1016/0014-5793(80)80569-2 · Cited by 58 · see citing works

Molecular Profiling and Relationship with Clinical Response in Patients with IDH1 Mutation-Positive Hematologic Malignancies Receiving AG-120, a First-in-Class Potent Inhibitor of Mutant IDH1, in Addition to Data from the Completed Dose Escalation Portion of the Phase 1 Study

Dinardo, C. D., de Botton, S., Pollyea, D. A., Stein, E. M., Fathi, A. T., Roboz, G. J., Collins, R. H., Swords, R. T., Flinn, I. W., Altman, J. K., et al. (2015) · Blood · doi:10.1182/blood.v126.23.1306.1306 · Cited by 57 · see citing works

Characterization of gene mutations and copy number changes in acute myeloid leukemia using a rapid target enrichment protocol

Bolli, N., Manes, N., McKerrell, T., Chi, J., Park, N., Gundem, G., Quail, M. A., Sathiaseelan, V., Herman, B., Crawley, C. R., et al. (2014) · Haematologica · doi:10.3324/haematol.2014.113381 · Cited by 52 · see citing works

Mitochondrial 2-hydroxyglutarate metabolism

Engqvist, M. K. M., Eßer, C., Maier, A., Lercher, M. J., & Maurino, V. G. (2014) · Mitochondrion · doi:10.1016/j.mito.2014.02.009 · Cited by 41 · see citing works

Investigations by mass isotopomer analysis of the formation of D ‐2‐hydroxyglutarate by cultured lymphoblasts from two patients with D ‐2‐hydroxyglutaric aciduria

Struys, E. A., Verhoeven‐Duif, N. M., Brunengraber, H., & Jakobs, C. (2003) · FEBS Letters · doi:10.1016/s0014-5793(03)01459-5 · Cited by 40 · see citing works

IDH1, lipid metabolism and cancer: Shedding new light on old ideas

Bogdanovic, E. (2015) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2015.04.014 · Cited by 39 · see citing works

Isotope effect studies of chicken liver NADP malic enzyme: role of the metal ion and viscosity dependence

Grissom, C. B., & Cleland, W. W. (1988) · Biochemistry · doi:10.1021/bi00408a039 · Cited by 30 · see citing works

Identification and Characterization of Small-Molecule Inhibitors of the R132H/R132H Mutant Isocitrate Dehydrogenase 1 Homodimer and R132H/Wild-Type Heterodimer

Brooks, E. E., Wu, X., Hanel, A., Nguyen, S., Wang, J., Zhang, J. H., Harrison, A., & Zhang, W. (2014) · SLAS DISCOVERY · doi:10.1177/1087057114541148 · Cited by 29 · see citing works

Discovery of 8-Membered Ring Sulfonamides as Inhibitors of Oncogenic Mutant Isocitrate Dehydrogenase 1

Law, J. M., Stark, S., Liu, K., Liang, N. E., Hussain, M. M., Leiendecker, M., Ito, D., Verho, O., Stern, A. M., Johnston, S. E., et al. (2016) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.6b00264 · Cited by 28 · see citing works

AG-221, an oral, selective, first-in-class, potent IDH2-R140Q mutant inhibitor, induces differentiation in a xenotransplant model

Quivoron, C., David, M., Straley, K., Travins, J., Kim, H., Chen, Y., Zhu, D., Saada, V., Bawa, O., Opolon, P., et al. (2014) · Blood · doi:10.1182/blood.v124.21.3735.3735 · Cited by 19 · see citing works

A small molecule inhibitor of mutant IDH2 rescues cardiomyopathy in a D‐2‐hydroxyglutaric aciduria type II mouse model

Wang, F., Travins, J. M., Lin, Z., Si, Y., Chen, Y., Powe, J., Murray, S., Zhu, D., Artin, E., Größ, S., et al. (2016) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-016-9960-y · Cited by 16 · see citing works

The Energy‐Linked Transhydrogenase in Rat Liver in Relation to the Reductive Carboxylation of 2‐Oxoglutarate

WANDERS, R. J. A., DOORN, H. E. V., & Tager, J. M. (1981) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1981.tb05379.x · Cited by 14 · see citing works

Evidence that 2-hydroxyglutarate is not readily metabolized in colorectal carcinoma cells

Gelman, S. J., Mahieu, N. G., Cho, K., Llufrio, E. M., Wencewicz, T. A., & Patti, G. J. (2015) · Cancer & Metabolism · doi:10.1186/s40170-015-0139-z · Cited by 13 · see citing works

IDH1 regulates phospholipid metabolism in developing astrocytes

Bogdanovic, E., Sadri, A.-R., Catapano, M. S., Vance, J. E., & Jeschke, M. G. (2014) · Neuroscience Letters · doi:10.1016/j.neulet.2014.09.015 · Cited by 11 · see citing works

Drug Candidates Unveiled In Boston

Halford, B. A. (2015) · Chemical & Engineering News · doi:10.1021/cen-09338-scitech1 · Cited by 2 · see citing works

Hallmarks of Cancer: New Dimensions

Hanahan, D. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-1059 · Cited by 9,887 · see citing works

Oxidative Stress in Cancer

Hayes, J. D., Dinkova-Kostova, A. T., & Tew, K. D. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.06.001 · Cited by 2,654 · see citing works

Discovery of AG-120 (Ivosidenib): A First-in-Class Mutant IDH1 Inhibitor for the Treatment of IDH1 Mutant Cancers

Popovici-Müller, J. V., Lemieux, R. M., Artin, E., Saunders, J. O., Salituro, F. G., Travins, J. M., Cianchetta, G., Cai, Z., Zhou, D., Cui, D., et al. (2018) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.7b00421 · Cited by 457 · see citing works

Synthetic lethal therapies for cancer: what’s next after PARP inhibitors?

Ashworth, A., & Lord, C. J. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0055-6 · Cited by 420 · see citing works

Coupling Krebs cycle metabolites to signalling in immunity and cancer

Ryan, D. G., Murphy, M. P., Frezza, C., Prag, H. A., Chouchani, E. T., O’Neill, L. A., & Mills, E. L. (2018) · Nature Metabolism · doi:10.1038/s42255-018-0014-7 · Cited by 398 · see citing works

Biological Role and Therapeutic Potential of IDH Mutations in Cancer

Waitkus, M. S., Diplas, B. H., & Yan, H. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.04.011 · Cited by 334 · see citing works

The NCI Genomic Data Commons as an engine for precision medicine

Jensen, M. A., Ferretti, V., Grossman, R. L., & Staudt, L. M. (2017) · Blood · doi:10.1182/blood-2017-03-735654 · Cited by 317 · see citing works

NAD+ Metabolism Maintains Inducible PD-L1 Expression to Drive Tumor Immune Evasion

Lv, H., Lv, G., Chen, C., Zong, Q., Jiang, G., Ye, D., Cui, X., He, Y., Xiang, W., Han, Q. Y., et al. (2020) · Cell Metabolism · doi:10.1016/j.cmet.2020.10.021 · Cited by 301 · see citing works

Eight Kinetically Stable but Thermodynamically Activated Molecules that Power Cell Metabolism

Walsh, C. T., Tu, B. P., & Tang, Y. (2017) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00510 · Cited by 302 · see citing works

Metabolism, Activity, and Targeting of D- and L-2-Hydroxyglutarates

Ye, D., Guan, K.-L., & Xiong, Y. (2018) · Trends in Cancer · doi:10.1016/j.trecan.2017.12.005 · Cited by 242 · see citing works

Wild-type and mutated IDH1/2 enzymes and therapy responses

Molenaar, R. J., Maciejewski, J. P., Wilmink, J. W., & Noorden, C. J. F. V. (2018) · Oncogene · doi:10.1038/s41388-017-0077-z · Cited by 243 · see citing works

The cancer driver genes IDH1/2, JARID1C/ KDM5C, and UTX/ KDM6A: crosstalk between histone demethylation and hypoxic reprogramming in cancer metabolism

Chang, S., Yim, S., & Park, H. (2019) · Experimental &amp; Molecular Medicine · doi:10.1038/s12276-019-0230-6 · Cited by 228 · see citing works

Safety and activity of ivosidenib in patients with IDH1-mutant advanced cholangiocarcinoma: a phase 1 study

Lowery, M. A., Burris, H. A., Jankú, F., Shroff, R. T., Cleary, J. M., Azad, N. S., Goyal, L., Maher, E. A., Gore, L., Hollebecque, A., et al. (2019) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(19)30189-x · Cited by 223 · see citing works

The Role for Myc in Coordinating Glycolysis, Oxidative Phosphorylation, Glutaminolysis, and Fatty Acid Metabolism in Normal and Neoplastic Tissues

Goetzman, E. S., & Prochownik, E. V. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00129 · Cited by 199 · see citing works

Advances in the Knowledge of the Molecular Biology of Glioblastoma and Its Impact in Patient Diagnosis, Stratification, and Treatment

Delgado-Martín, B., & Medina, M. Á. (2020) · Advanced Science · doi:10.1002/advs.201902971 · Cited by 192 · see citing works

Small molecule inhibitors targeting the cancers

Liu, G., Chen, T., Zhang, X., Ma, X., & Shi, H. (2022) · MedComm · doi:10.1002/mco2.181 · Cited by 198 · see citing works

TRIM21 and PHLDA3 negatively regulate the crosstalk between the PI3K/AKT pathway and PPP metabolism

Cheng, J., Huang, Y., Zhang, X., Yu, Y., Wu, S., Jiao, J., Tran, L. M., Zhang, W., Liu, R., Zhang, L., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15819-3 · Cited by 151 · see citing works

Dysregulation of the TET family of epigenetic regulators in lymphoid and myeloid malignancies

Lio, C. J., Yuita, H., & Rao, A. (2019) · Blood · doi:10.1182/blood.2019791475 · Cited by 146 · see citing works

Oncogenic Activities of IDH1/2 Mutations: From Epigenetics to Cellular Signaling

Gagné, L. M., Boulay, K., Topisirović, I., Huot, M., & Mallette, F. A. (2017) · Trends in Cell Biology · doi:10.1016/j.tcb.2017.06.002 · Cited by 141 · see citing works

TET Enzymes and 5hmC in Adaptive and Innate Immune Systems

Lio, C. J., & Rao, A. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00210 · Cited by 139 · see citing works

Regorafenib induces lethal autophagy arrest by stabilizing PSAT1 in glioblastoma

Jiang, J., Zhang, L., Chen, H., Lei, Y., Zhang, T., Wang, Y., Jin, P., Lan, J., Zhou, L., Huang, Z., et al. (2019) · Autophagy · doi:10.1080/15548627.2019.1598752 · Cited by 135 · see citing works

2-Hydroxyglutarate in Cancer Cells

Ježek, P. (2020) · Antioxidants &amp; Redox Signaling · doi:10.1089/ars.2019.7902 · Cited by 130 · see citing works

SIRT2‐dependent IDH1 deacetylation inhibits colorectal cancer and liver metastases

Wang, B., Ye, Y., Yang, X. P., Liu, B., Wang, Z., Chen, S., Jiang, K., Zhang, W., Jiang, H., Mustonen, H. K., et al. (2020) · EMBO Reports · doi:10.15252/embr.201948183 · Cited by 125 · see citing works

Aberrant DNA Methylation in Colorectal Cancer: What Should We Target?

Tse, J. W. T., Jenkins, L. J., Chionh, F. J. M., & Mariadason, J. M. (2017) · Trends in cancer · doi:10.1016/j.trecan.2017.08.003 · Cited by 125 · see citing works

Connections Between Metabolism and Epigenetics in Programming Cellular Differentiation

Chisolm, D. A., & Weinmann, A. S. (2018) · Annual Review of Immunology · doi:10.1146/annurev-immunol-042617-053127 · Cited by 129 · see citing works

Mitochondria as a target in cancer treatment

Liu, Y., & Shi, Y. (2020) · MedComm · doi:10.1002/mco2.16 · Cited by 120 · see citing works

Nicotinamide riboside attenuates age-associated metabolic and functional changes in hematopoietic stem cells

Sun, X., Cao, B., Naval-Sánchez, M., Pham, T. A., Sun, Y., Williams, B., Heazlewood, S. Y., Deshpande, N., Li, J., Kraus, F., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22863-0 · Cited by 118 · see citing works

Metabolic Regulation of Redox Balance in Cancer

Purohit, V., Simeone, D. M., & Lyssiotis, C. A. (2019) · Cancers · doi:10.3390/cancers11070955 · Cited by 115 · see citing works

Mutant IDH1 inhibition induces dsDNA sensing to activate tumor immunity

Wu, M., Kondo, H., Kammula, A. V., Shi, L., Xiao, Y., Dhiab, S., Xu, Q., Slater, C. J., Avila, O. I., Merritt, J., et al. (2024) · Science · doi:10.1126/science.adl6173 · Cited by 103 · see citing works

Metabolic Plasticity of Tumor Cell Mitochondria

Cannino, G., Ciscato, F., Masgras, I., Sànchez‐Martìn, C., & Rasola, A. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00333 · Cited by 96 · see citing works

Consumption of NADPH for 2-HG Synthesis Increases Pentose Phosphate Pathway Flux and Sensitizes Cells to Oxidative Stress

Gelman, S. J., Naser, F. J., Mahieu, N. G., McKenzie, L. D., Dunn, G. P., Chheda, M. G., & Patti, G. J. (2018) · Cell Reports · doi:10.1016/j.celrep.2017.12.050 · Cited by 95 · see citing works

The multifaceted contribution of α-ketoglutarate to tumor progression: An opportunity to exploit?

Abla, H., Sollazzo, M., Gasparre, G., Iommarini, L., & Porcelli, A. M. (2019) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2019.05.031 · Cited by 96 · see citing works

The first-in-human phase I study of a brain-penetrant mutant IDH1 inhibitor DS-1001 in patients with recurrent or progressive IDH1-mutant gliomas

Natsume, A., Arakawa, Y., Narita, Y., Sugiyama, K., Hata, N., Muragaki, Y., Shinojima, N., Kumabe, T., Saito, R., Motomura, K., et al. (2023) · Neuro-Oncology · doi:10.1093/neuonc/noac155 · Cited by 93 · see citing works

Metabolism within the tumor microenvironment and its implication on cancer progression: An ongoing therapeutic target

Ocaña, M. C., Martı́nez-Poveda, B., Quesada, A. R., & Medina, M. Á. (2018) · Medicinal Research Reviews · doi:10.1002/med.21511 · Cited by 91 · see citing works

In cancer, all roads lead to NADPH

Rather, G. M., Pramono, A. A., Székely, Z., Bertino, J. R., & Tedeschi, P. M. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107864 · Cited by 91 · see citing works

NAD- and NADPH-Contributing Enzymes as Therapeutic Targets in Cancer: An Overview

Pramono, A. A., Rather, G. M., Herman, H., Lestari, K., & Bertino, J. R. (2020) · Biomolecules · doi:10.3390/biom10030358 · Cited by 88 · see citing works

Recent advances of IDH1 mutant inhibitor in cancer therapy

Tian, W., Zhang, W., Wang, Y., Jin, R., Wang, Y., Guo, H., Tang, Y., & Yao, X. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.982424 · Cited by 88 · see citing works

Friend or foe—IDH1 mutations in glioma 10 years on

Huang, L. E. (2019) · Carcinogenesis · doi:10.1093/carcin/bgz134 · Cited by 82 · see citing works

Delivering the Promise of Gene Therapy with Nanomedicines in Treating Central Nervous System Diseases

Luo, M., Lee, L. K. C., Peng, B., Choi, C. H. J., Tong, W. Y., & Voelcker, N. H. (2022) · Advanced Science · doi:10.1002/advs.202201740 · Cited by 81 · see citing works

Novel IDH1-Targeted Glioma Therapies

Karpel‐Massler, G., Nguyen, T. T. T., Shang, E., & Siegelin, M. D. (2019) · CNS Drugs · doi:10.1007/s40263-019-00684-6 · Cited by 82 · see citing works

Integrated Multi-omic Analysis of Esthesioneuroblastomas Identifies Two Subgroups Linked to Cell Ontogeny

Classe, M., Yao, H., Mouawad, R., Creighton, C. J., Burgess, A., Allanic, F., Wassef, M., Leroy, X., Vérillaud, B., Mortuaire, G., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.09.047 · Cited by 80 · see citing works

Signalling networks in cholangiocarcinoma: Molecular pathogenesis, targeted therapies and drug resistance

Fouassier, L., Marzioni, M., Afonso, M. B., Dooley, S., Gaston, K., Giannelli, G., Rodrigues, C. M. P., Lozano, E., Mancarella, S., Segatto, O., et al. (2019) · Liver International · doi:10.1111/liv.14102 · Cited by 78 · see citing works

Therapeutic potential of the mitochondria-targeted antioxidant MitoQ in mitochondrial-ROS induced sensorineural hearing loss caused by Idh2 deficiency

Kim, Y., Baek, J., Kim, S. H., Kim, M.-A., Lee, B., Ryu, N., Kim, K., Choi, D.-G., Kim, H.-M., Murphy, M. P., et al. (2018) · Redox Biology · doi:10.1016/j.redox.2018.11.013 · Cited by 64 · see citing works

PI3K/mTOR inhibition of IDH1 mutant glioma leads to reduced 2HG production that is associated with increased survival

Batsios, G., Viswanath, P., Subramani, E., Najac, C., Gillespie, A. M., Santos, R. D., Molloy, A. R., Pieper, R. O., & Ronen, S. M. (2019) · Scientific Reports · doi:10.1038/s41598-019-47021-x · Cited by 60 · see citing works

Cytosolic and mitochondrial NADPH fluxes are independently regulated

Niu, X., Stancliffe, E., Gelman, S. J., Wang, L., Schwaiger-Haber, M., Rowles, J. L., Shriver, L. P., & Patti, G. J. (2023) · Nature Chemical Biology · doi:10.1038/s41589-023-01283-9 · Cited by 60 · see citing works

Glutamine metabolism in Th17/Treg cell fate: applications in Th17 cell-associated diseases

Yang, G., Xia, Y., & Ren, W. (2020) · Science China Life Sciences · doi:10.1007/s11427-020-1703-2 · Cited by 55 · see citing works

IDH Inhibitors in AML—Promise and Pitfalls

McMurry, H. S., Fletcher, L. B., & Traer, E. A. (2021) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-021-00619-3 · Cited by 56 · see citing works

Metabolic adaptations in cancers expressing isocitrate dehydrogenase mutations

Hvinden, I. C., Cadoux-Hudson, T. A. D., Schofield, C. J., & McCullagh, J. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100469 · Cited by 59 · see citing works

Signaling metabolite L-2-hydroxyglutarate activates the transcription factor HIF-1α in lipopolysaccharide-activated macrophages

Williams, N. C., Ryan, D. G., Costa, A. S. H., Mills, E. L., Jedrychowski, M. P., Cloonan, S. M., Frezza, C., & O'Neill, L. A. J. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.101501 · Cited by 56 · see citing works

2-Hydroxyglutarate-Mediated Autophagy of the Endoplasmic Reticulum Leads to an Unusual Downregulation of Phospholipid Biosynthesis in Mutant IDH1 Gliomas

Viswanath, P., Radoul, M., Izquierdo-García, J. L., Ong, W. Q., Luchman, H. A., Cairncross, J. G., Huang, B., Pieper, R. O., Phillips, J. J., & Ronen, S. M. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-2926 · Cited by 54 · see citing works

Mitochondrial remodeling in colorectal cancer initiation, progression, metastasis, and therapy: A review

Abdelmaksoud, N. M., Abulsoud, A. I., Abdelghany, T. M., Elshaer, S. S., Rizk, S. M., & Senousy, M. A. (2023) · Pathology - Research and Practice · doi:10.1016/j.prp.2023.154509 · Cited by 53 · see citing works

Therapies for IDH-Mutant Gliomas

Nasany, R. A., & de la Fuente, M. I. (2023) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-023-01265-3 · Cited by 50 · see citing works

A feedback loop engaging propionate catabolism intermediates controls mitochondrial morphology

Zhou, J., Duan, M., Wang, X., Zhang, F., Zhou, H., Ma, T., Yin, Q., Zhang, J., Tian, F., Wang, G., et al. (2022) · Nature Cell Biology · doi:10.1038/s41556-022-00883-2 · Cited by 47 · see citing works

Oncometabolites in cancer aggressiveness and tumour repopulation

Dando, I., Pozza, E. D., Ambrosini, G., Torrens‐Mas, M., Butera, G., Mullappilly, N., Pacchiana, R., Palmieri, M., & Donadelli, M. (2019) · Biological reviews/Biological reviews of the Cambridge Philosophical Society · doi:10.1111/brv.12513 · Cited by 49 · see citing works

Loss of IDH2 Accelerates Age-related Hearing Loss in Male Mice

White, K., Kim, M., Han, C. J., Park, H., Ding, D., Boyd, K., Walker, L., Linser, P. J., Meneses, Z., Slade, C., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-23436-w · Cited by 46 · see citing works

Mutant IDH1 gliomas downregulate phosphocholine and phosphoethanolamine synthesis in a 2-hydroxyglutarate-dependent manner

Viswanath, P., Radoul, M., Izquierdo-García, J. L., Luchman, H. A., Cairncross, J. G., Pieper, R. O., Phillips, J. J., & Ronen, S. M. (2018) · Cancer & Metabolism · doi:10.1186/s40170-018-0178-3 · Cited by 46 · see citing works

Biliary Tract Cancers: Molecular Heterogeneity and New Treatment Options

Personeni, N., Lleò, A., Pressiani, T., Colapietro, F., Openshaw, M. R., Stavraka, C., Pouptsis, A., Pinato, D. J., & Rimassa, L. (2020) · Cancers · doi:10.3390/cancers12113370 · Cited by 45 · see citing works

Advances in targeted therapy of cholangiocarcinoma

Li, Y., Yu, J., Zhang, Y., Peng, C., Song, Y., & Liu, S. (2024) · Annals of Medicine · doi:10.1080/07853890.2024.2310196 · Cited by 48 · see citing works

Macrophage activation as an archetype of mitochondrial repurposing

Jones, A. E., & Divakaruni, A. S. (2020) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2019.100838 · Cited by 39 · see citing works

Enasidenib and ivosidenib in AML

Martelli, M. P., Martino, G., Cardinali, V., Falini, B., Martinelli, G., & Cerchione, C. (2020) · Minerva Medica · doi:10.23736/s0026-4806.20.07024-x · Cited by 42 · see citing works

Metabolic Regulation of Hypoxia-Inducible Transcription Factors: The Role of Small Molecule Metabolites and Iron

Bailey, P. S. J., & Nathan, J. A. (2018) · Biomedicines · doi:10.3390/biomedicines6020060 · Cited by 41 · see citing works

Whole-genome analysis of TET dioxygenase function in regulatory T cells

Yue, X., Samaniego‐Castruita, D., González‐Avalos, E., Li, X., Barwick, B. G., & Rao, A. (2021) · EMBO Reports · doi:10.15252/embr.202152716 · Cited by 37 · see citing works

Detection of Circulating Tumor DNA Methylation in Diagnosis of Colorectal Cancer

Xu, F., Yu, S., Han, J., Zong, M., Tan, Q., Zeng, X. Y., & Fan, L. (2021) · Clinical and Translational Gastroenterology · doi:10.14309/ctg.0000000000000386 · Cited by 40 · see citing works

Malic enzyme 2 maintains protein stability of mutant p53 through 2-hydroxyglutarate

Zhao, M., Yao, P., Mao, Y., Wu, J., Wang, W., Geng, C., Cheng, J., Du, W., & Jiang, P. (2022) · Nature Metabolism · doi:10.1038/s42255-022-00532-w · Cited by 40 · see citing works

IDH3γ functions as a redox switch regulating mitochondrial energy metabolism and contractility in the heart

Nanadikar, M. S., Leon, A. M. V., Guo, J., van Belle, G. J., Jatho, A., Philip, E. S., Brandner, A. F., Böckmann, R. A., Shi, R., Zieseniß, A., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-37744-x · Cited by 38 · see citing works

Magnetic resonance spectroscopy for the study of cns malignancies

Ruiz‐Rodado, V., Brender, J., Cherukuri, M. K., Gilbert, M. R., & Larion, M. (2020) · Progress in Nuclear Magnetic Resonance Spectroscopy · doi:10.1016/j.pnmrs.2020.11.001 · Cited by 37 · see citing works

GABA, glutamine, glutamate oxidation and succinic semialdehyde dehydrogenase expression in human gliomas

Hujber, Z., Horváth, G., Petővári, G., Krencz, I., Dankó, T., Mészáros, K. V., Rajnai, H., Szoboszlai, N., Leenders, W. P. J., Jeney, A., et al. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0946-5 · Cited by 38 · see citing works

Metabolic Drivers in Hereditary Cancer Syndromes

Sciacovelli, M., Schmidt, C., Maher, E. R., & Frezza, C. (2019) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030419-033612 · Cited by 37 · see citing works

Evolving Treatment Strategies for Elderly Leukemia Patients with IDH Mutations

Buege, M. J., DiPippo, A. J., & Dinardo, C. D. (2018) · Cancers · doi:10.3390/cancers10060187 · Cited by 35 · see citing works

2-Oxoglutarate derivatives can selectively enhance or inhibit the activity of human oxygenases

Nakashima, Y., Brewitz, L., Tumber, A., Salah, E., & Schofield, C. J. (2021) · Nature Communications · doi:10.1038/s41467-021-26673-2 · Cited by 37 · see citing works

The regulatory mechanisms and inhibitors of isocitrate dehydrogenase 1 in cancer

Liu, Y., Xu, W., Li, M., Yang, Y., Sun, D., Chen, L., Li, H., & Chen, L. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.12.019 · Cited by 35 · see citing works

Circles of Life: linking metabolic and epigenetic cycles to immunity

Lio, C. J., & Huang, S. C. (2020) · Immunology · doi:10.1111/imm.13207 · Cited by 34 · see citing works

Synthesis and evaluation of radiolabeled AGI-5198 analogues as candidate radiotracers for imaging mutant IDH1 expression in tumors

Chitneni, S. K., Reitman, Z. J., Spicehandler, R., Gooden, D. M., Yan, H., & Zalutsky, M. R. (2018) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2018.01.015 · Cited by 32 · see citing works

Recent Advances in the Targeting of Epigenetic Regulators in B-Cell Non-Hodgkin Lymphoma

Ribeiro, M. L., Reyes-Garau, D., Armengol, M., Fernández-Serrano, M., & Roué, G. (2019) · Frontiers in Genetics · doi:10.3389/fgene.2019.00986 · Cited by 34 · see citing works

Wild-type IDH2 contributes to Epstein–Barr virus-dependent metabolic alterations and tumorigenesis

Shi, F., He, Y., Li, J., Tang, M., Li, Y., Xie, L., Zhao, L., Hu, J., Luo, X., Zhou, M., et al. (2020) · Molecular Metabolism · doi:10.1016/j.molmet.2020.02.009 · Cited by 32 · see citing works

Targeting Immunometabolism in Glioblastoma

Mohan, A. A., Tomaszewski, W. H., Haskell-Mendoza, A. P., Hotchkiss, K. M., Singh, K., Reedy, J. L., Fecci, P. E., Sampson, J. H., & Khasraw, M. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.696402 · Cited by 32 · see citing works

The roles of NADPH and isocitrate dehydrogenase in cochlear mitochondrial antioxidant defense and aging

White, K., & Someya, S. (2022) · Hearing Research · doi:10.1016/j.heares.2022.108659 · Cited by 31 · see citing works

The hematopoietic stem cell diet

Wilkinson, A. C., & Yamazaki, S. (2018) · International Journal of Hematology · doi:10.1007/s12185-018-2451-1 · Cited by 29 · see citing works

R-2HG downregulates ERα to inhibit cholangiocarcinoma via the FTO/m6A-methylated ERα/miR16-5p/YAP1 signal pathway

Gao, Y., Ouyang, X., Zuo, L., Xiao, Y., Sun, Y., Chang, C., Qin, X., & Yeh, S. (2021) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2021.06.017 · Cited by 30 · see citing works

2-Hydroxyglutarate in Acute Myeloid Leukemia: A Journey from Pathogenesis to Therapies

Raimondi, V., Ciotti, G., Gottardi, M., & Ciccarese, F. (2022) · Biomedicines · doi:10.3390/biomedicines10061359 · Cited by 31 · see citing works

Detection of Metabolic Changes Induced via Drug Treatments in Live Cancer Cells and Tissue Using Raman Imaging Microscopy

Larion, M., Dowdy, T., Ruiz‐Rodado, V., Meyer, M. W., Song, H., Zhang, W., Davis, D. L., Gilbert, M. R., & Lita, A. (2018) · Biosensors · doi:10.3390/bios9010005 · Cited by 29 · see citing works

Wild-type IDH2 protects nuclear DNA from oxidative damage and is a potential therapeutic target in colorectal cancer

Qiao, S., Lu, W., Glorieux, C., Li, J., Zeng, P., Meng, N., Zhang, H., Wen, S., & Huang, P. (2021) · Oncogene · doi:10.1038/s41388-021-01968-2 · Cited by 30 · see citing works

Molecular and Morphological Changes Induced by Ivosidenib Correlate with Efficacy in Mutant- IDH1 Cholangiocarcinoma

Aguado-Fraile, E., Tassinari, A. M., Ishii, Y., Sigel, C., Lowery, M. A., Goyal, L., Gliser, C., Jiang, L., Pandya, S. S., Wu, B., et al. (2021) · Future Oncology · doi:10.2217/fon-2020-1274 · Cited by 28 · see citing works

Targeting Isocitrate Dehydrogenase Mutations in Cancer: Emerging Evidence and Diverging Strategies

Waitkus, M. S., & Yan, H. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-1827 · Cited by 26 · see citing works

Allosteric inhibitor remotely modulates the conformation of the orthestric pockets in mutant IDH2/R140Q

Chen, J., Yang, J., Sun, X., Wang, Z., Cheng, X., Lu, W., Cai, X., Hu, C., Shen, X., & Cao, P. (2017) · Scientific Reports · doi:10.1038/s41598-017-16427-w · Cited by 26 · see citing works

Oncometabolite 2-hydroxyglutarate regulates anti-tumor immunity

Cai, M., Zhao, J., Ding, Q., & Wei, J. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e24454 · Cited by 26 · see citing works

Novel epigenetic therapies in hematological malignancies: Current status and beyond

Gallipoli, P., & Huntly, B. J. P. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.07.005 · Cited by 25 · see citing works

Synthesis of 2-oxoglutarate derivatives and their evaluation as cosubstrates and inhibitors of human aspartate/asparagine-β-hydroxylase

Brewitz, L., Nakashima, Y., & Schofield, C. J. (2020) · Chemical Science · doi:10.1039/d0sc04301j · Cited by 25 · see citing works

Potent immunosuppressive effects of the oncometaboliteR-2-hydroxyglutarate

Galluzzi, L., & Kroemer, G. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1528815 · Cited by 25 · see citing works

Targeted inhibition of ubiquitin signaling reverses metabolic reprogramming and suppresses glioblastoma growth

Donne, R. D., Iannucci, R., Rinaldi, L., Roberto, L., Oliva, M. A., Senatore, E., Borzacchiello, D., Lignitto, L., Giurato, G., Rizzo, F. M., et al. (2022) · Communications Biology · doi:10.1038/s42003-022-03639-8 · Cited by 23 · see citing works

Pharmacokinetics, absorption, metabolism, and excretion of [14C]ivosidenib (AG-120) in healthy male subjects

Prakash, C., Fan, B., Altaf, S. A., Agresta, S., Liu, H., & Yang, H. Q. (2019) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-019-03793-7 · Cited by 24 · see citing works

d-2-Hydroxyglutarate dehydrogenase plays a dual role in l-serine biosynthesis and d-malate utilization in the bacterium Pseudomonas stutzeri

Guo, X., Zhang, M., Cao, M., Zhang, W., Kang, Z., Xu, P., Ma, C., & Gao, C. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.003897 · Cited by 22 · see citing works

In vivo efficacy of mutant IDH1 inhibitor HMS-101 and structural resolution of distinct binding site

Chaturvedi, A., Goparaju, R., Gupta, C., Weder, J., Klünemann, T., Cruz, M. M. A., Kloos, A., Görlich, K., Schottmann, R., Othman, B., et al. (2019) · Leukemia · doi:10.1038/s41375-019-0582-x · Cited by 23 · see citing works

Pharmacological characterization of TQ 05310, a potent inhibitor of isocitrate dehydrogenase 2 R140Q and R172K mutants

Gao, M., Zhu, H., Li, F., Li, Y., Bao, X., Fu, H., Quan, H., Wang, L., & Lou, L. (2019) · Cancer Science · doi:10.1111/cas.14152 · Cited by 21 · see citing works

Wild-Type Isocitrate Dehydrogenase-Dependent Oxidative Decarboxylation and Reductive Carboxylation in Cancer and Their Clinical Significance

He, Q., Chen, J., Xie, Z., & Chen, Z. (2022) · Cancers · doi:10.3390/cancers14235779 · Cited by 24 · see citing works

Exploring the functional roles of small-molecule metabolites in disease research: Recent advancements in metabolomics

Tan, A., & Ma, X. (2023) · Chinese Chemical Letters · doi:10.1016/j.cclet.2023.109276 · Cited by 22 · see citing works

Preclinical toxicology profile of squalene epoxidase inhibitors

Nagaraja, R., Olaharski, A. J., Narayanaswamy, R., Mahoney, C. E., Pirman, D. A., Größ, S., Roddy, T. P., Popovici-Müller, J. V., Smolen, G. A., & Silverman, L. R. (2020) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2020.115103 · Cited by 21 · see citing works

A Mitochondria-Targeted Fluorescent Probe for Monitoring NADPH Overproduction during Influenza Virus Infection

Chang, H., Hu, X., Tang, X., Tian, S., Li, Y., Lv, X., & Shang, L. (2023) · ACS Sensors · doi:10.1021/acssensors.2c02458 · Cited by 21 · see citing works

Loss of H3K27 trimethylation is frequent in IDH1-R132H but not in non-canonical IDH1/2 mutated and 1p/19q codeleted oligodendroglioma: a Japanese cohort study

Habiba, U., Sugino, H., Yordanova, R., Ise, K., Tanei, Z., Ishida, Y., Tanikawa, S., Terasaka, S., Sato, K., Kamoshima, Y., et al. (2021) · Acta Neuropathologica Communications · doi:10.1186/s40478-021-01194-7 · Cited by 21 · see citing works

Intrahepatic cholangiocarcinoma: Insights on molecular testing, targeted therapies, and future directions from a multidisciplinary panel

Gujarathi, R., Peshin, S., Zhang, X., Bachini, M., Meeks, M. N., Shroff, R. T., & Pillai, A. (2025) · Hepatology Communications · doi:10.1097/hc9.0000000000000743 · Cited by 21 · see citing works

Isocitrate dehydrogenase mutations: new opportunities for translational research

Keum, Y., & Choi, B. Y. (2015) · BMB Reports · doi:10.5483/bmbrep.2015.48.5.021 · Cited by 11 · see citing works

Development of Novel Therapeutics Targeting Isocitrate Dehydrogenase Mutations in Cancer

Sharma, H. (2018) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026618666180518091144 · Cited by 35 · see citing works

IDH mutations in cancer and progress toward development of targeted therapeutics

Dang, L., Yen, K., & Attar, E. C. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw013 · Cited by 509 · see citing works

How Metabolism Informs Cancer Drug Discovery

Biller, S. A. (2012) · The FASEB Journal · doi:10.1096/fasebj.26.1_supplement.356.1

Isocitrate Dehydrogenase Mutations in Human Cancers: Physiopathologic Mechanisms and Therapeutic Targeting

malignancy, A. I. A. H. H., mutations, C. B. T. A. O. V. S. G. A. A. O. I. M. C. A. A. V. S. O. M. S. C. O. I. T. L. 2. D. H. L. T. T. I. O. T. B. T. O. G., (HPCs), W. C. T. S. D. O. T. L. P. T. C. I. M. C. A. S. A. T. H. S. C. (. A. P. C., in, S. A. T. M., of, T. L., in, O. T. M., HPCs, R. T. K. T. C. I. M. P. S.-R. A. B. T. D. O., involving, S. A. T. T. F., & involving, O. T. T. F. (2016) · Journal of Exploratory Research in Pharmacology · doi:10.14218/jerp.2016.00019 · Cited by 7 · see citing works